Roivant Sciences, Inc.
NEWS
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
Nabriva Therapeutics reported positive topline results from its Phase III clinical trial of oral lefamulin compared to oral moxifloxacin in adults with moderate community-acquired bacterial pneumonia (CABP).
Biotech investor Vivek Ramaswamy has launched another company. This time his company, dubbed Genevant, will focus on the development of RNA-based therapies and is the combined product of Roivant Sciences and Arbutus Biopharma Corporation.
Ligand Pharmaceuticals is licensing LGD-6972, a glucagon receptor antagonist (GRA), to Roivant Sciences for $20 million.
With the deal in hand, Roivant has stepped into the world of metabolic diseases.
Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra.
JOBS
IN THE PRESS